Research Article

Rank Protein Immunolabeling during Bone-Implant Interface Healing Process

Francisley Ávila Souza, 1 Thallita Pereira Queiroz, 1 Eloá Rodrigues Luvizuto, 1 Renato Sussumu Nishioka, 2 Idelmo Rangel Garcia-JR, 1 Paulo Sérgio Perri de Carvalho, 1 and Roberta Okamoto 1

1 Department of Surgery and General Clinical, Araçatuba Dental School, Universidade Estadual Paulista, UNESP, Rua José Bonifácio 1190, Bloco 10A, Vila Mendoça, 16015-050 Araçatuba, Brazil
2 Department of Dental Materials and Prothesis, São José dos Campos Dental School, Universidade Estadual Paulista, UNESP, Brazil

Correspondence should be addressed to Francisley Ávila Souza, f.avilasouza@ig.com.br

Received 24 March 2010; Revised 18 June 2010; Accepted 18 June 2010

1. Introduction

Of the significant advances in dentistry during the twentieth century, unquestionably none has extended the treatment horizons more than the successful use of osseointegrated implants. Applying the principles of osseointegration, dental surgeons are predictably able to replace missing teeth with excellent long-term esthetic and functional results [1].

Bränemark et al. [2] have defined osseointegration as a direct structural and functional connection between ordinary healthy bone and the implant surface, as seen at the level of optical microscopy, producing stability and allowing the structure to support the masticatory forces. A release of growth factors takes place right after an implant is inserted, which stimulates osteoblast precursors to develop into mature osteoblasts with consecutive production of bone tissue [3]. The process of bone remodeling, which involves many cellular steps and is not yet well understood, has been considered a repetition of the osteogenic lineage response that occurs in the fetus during the developmental phases [4].

The initial step in the bone-healing process starts with the migration of osteogenic cells, derived from the medullary bone layer, including undifferentiated mesenchymal cells, osteocytes, and osteoblasts, directly to a framework supported by blood a clot [5, 6]. The anabolic model is the first response of bone healing after implant placement in the cortical bone, similar to the process that occurs in fracture healing [7]. Thus, biologically, there is no evidence of complete contact between bone and the titanium surface, but the aspect considered is the greater or lesser amount of connective tissue, without clinical failure or fault of the implant [8]. In machined-surface implants, there is a larger quantity of conjunctive tissue in the initial stages of the repair process, when compared with porous-surface implants.

Therefore, the repair process around machined-surface implants is time-dependant [9, 10]. This occurs because
the implant surface has a smaller area of contact [11]. It is believed that retention of the blood clot is less stable, and consequently the migration of cells of osteoblastic origin occurs more slowly on machined surface implants. Therefore, the bone-interface contact in machined-surface implants is smaller in the initial stages of the repair process when compared with porous surface implants [9, 12].

The recent discovery of the proteins of the TNF family members has shown their roles in bone dynamics [13–16]. From these proteins, RANK is expressed in osteoclast lineage cells [16], controlling bone resorption [17], and consecutively, calcium metabolism. The function of RANK protein is related to two other bone-matrix proteins, RANKL (receptor activator of nuclear factor kappa B ligand) and OPG (osteoprotegerin) [18]; the interaction among them will modulate bone turnover.

Considering the involvement of RANK, a TNF family member receptor-activator of nuclear factor kappa B, in bone turnover as the main pathway to achieve bone homeostasis, the purpose of this paper was to evaluate RANK immuno-labeling during the bone-implant interface healing process during different periods of its chronology.

2. Material and Methods

2.1. Animals. Twenty male Wistar rats, weighing between 300 and 350 g, 90 days old were maintained at a temperature of 22° C, in a 12-h light/12-h dark cycle, ad libitum to water and rat food. The principles of laboratory animal care (NIH publication 85-23, 1985) [19] and national laws on animal use were complied with in the present study, which was authorized by the Animal Research Ethics Committee of the São Paulo State University, Brazil (Protocol Number 36/05).

2.2. Surgical Procedure. The animals received general anesthesia with xylazine (0.03 mL/100 g bw/im—Dopaser Laboratory S.A., Barcelona, Spain) and Ketamine (0.07 mL/100 g bw/im—Fort Dodge Saúde Animal Ltda, Brazil). After trichotomy and antisepsis (Polyvinylpyrrolidone iodide; Indústria Química e Farmacêutica Rioquímica Brazil), the animals received a subcutaneous injection of 0.07 mL of 0.5% bupivacaine hydrochloride; Indústria Química e Farmacêutica Rioquímica Brazil) and implant placement was performed with a digital key 1.17 (SIN, Sistema de Implante Nacional, São Paulo, Brasil) which was carefully fitted into the internal hexagon of the implant. Therefore, they were removed after the decalcification process, and it may also be mentioned that in the act of inserting the implant, it was developed especially for this study, with the dimensions already described and with an internal hexagon 1.20 mm in diameter.

Transversal sections to the area corresponding to the implants were cut on a cryostat (Micron Zeiss, Berlin, Germany) to obtain 1 mm thick slices, thin enough to allow an immunohistochemical analysis, which were mounted on previously gelatinized slides.

2.3. Collection of Materials. After the experimental periods, the animals were anaesthetized and infusion with 4% formaldehyde (Acros Organics, New Jersey, USA), was performed using a Masterflex LS perfusion pump (Cole-Parmer Instrument Company, Vermont Hills, IL, USA), to remove the right tibia. The bone blocks were postfixed in 4% formaldehyde, demineralized in 5% EDTA (Merck, Darmstadt, Germany) and cryoprotected in sucrose (Merck, Darmstadt, Germany). After this, the implants were removed with the use of a 1.17 key (SIN, Sistema de Implante Nacional, São Paulo, Brasil) which was carefully fitted into the internal hexagon of the implant, so as not to cause injury to the bone tissue around the implants. Therefore, they were removed after the decalcification process, and it may also be mentioned that in the act of inserting the implant, it was developed especially for this study, with the dimensions already described and with an internal hexagon 1.20 mm in diameter.

2.4. Immunohistochemical Processing. An anti-RANK primary antibody was used (Rabbit anti-RANK polyclonal—Santa Cruz Biotechnology, California, USA). As a secondary antibody, a biotinylated donkey antirabbit antibody (Jackson Immunoresearch Laboratories, West Grove, Pennsylvania, USA) was used. The immunohistochemical reaction was amplified with an avidin biotin system (Kit ABC—Vectastain Elite ABC—Peroxidase Standard, reagent A and B only—PK6100—Vector Laboratories, Burlingame, CA, USA) and diaminobenzidine (Sigma Aldrich, St Louis, Missouri, USA) was used as chromogen. Immunohistochemical reactions were controlled to evaluate the specificity of the labels omitting the primary antibody (negative controls). The analyses were performed without the knowledge of the examiner that was well calibrated. Positive control was performed in the nasal cavity of rats for the osteoclast and in primary bone of newborn rats for the osteoblast. Negative control was performed by omitting the primary antibody to see the veracity of the reaction.

Hematoxylin and eosin staining was performed and used as a reference of the cytoarchitecture of the tissue sides of the immunohistochemistry reactions; some slides were stained with Hematoxylin and eosin in order to receive the cytoarchitecture orientation. Data analysis was performed in a semiquantitative manner, with scores ranging from “−” for absence of marking and “+”, “++” and “+++” for little, medium, and a great deal of marking, respectively.

The transversal sections allowed visualization of the bone tissue formed in contact with the implant. The titanium implants were removed from the samples after the demineralization process was complete. Therefore, the area analyzed was that around the negative area of the implant. To facilitate comparisons, scores were converted into percentile averages frequencies of 0%, 20% (10% to 30%), 60% (50% to 70%), and 90% (*0% to 100%).
The results obtained considering the expression of RANK in osteoblasts (GI) and RANK in osteoclasts (GII) were joined, tabulated for analysis, and submitted to the Mann-Whitney test to compare each group with each period, and to the Kruskal-Wallis and Dunn Multiple Comparison nonparametric tests \((\alpha = 5\%)\) to compare each group in all periods. The cells stained by immunohistochemistry, which were shown to be multinucleated were considered to be osteoclasts, and those around or within the bone trabeculae that were not multinucleated, were considered osteoblasts.

### 3. Results

#### 3.1. Clinical Analysis
None of the implants failed. All the implants were stable, without loss of the surrounding bone.

**Qualitative Immunohistochemistry Analysis.** For immunohistochemistry analysis, the immunolabelings taken into consideration were those observed in the osteoclasts, osteoblasts, and osteocytes in neofomed bone, around the implant (negative area).

At 7 postoperative days, neofomed trabecular bone tissue was observed with osteoblasts located around it synthesizing bone matrix. In addition, connective tissue was observed in some areas close to the implant. RANK protein expression was observed in osteoblast lineage cells (Figure 2(a)).

At 14 postoperative days, a larger quantity of bone formation was observed. RANK immunolabeling was observed in osteocyte phenotypes and bone-lining cells. There was no expression in osteoblast phenotype cells in this period (Figure 2(b)). At 21 postoperative days, RANK expression was reduced when compared with previous periods and the morphology of the cells differed from the aspect observed at 7 postoperative days (Figure 2(c)). Dispersed trabecular bone was also observed, some cells with an aspect of bone-lining cells or latent osteocytes, with no metabolic activity. In some areas, it was possible to observe RANK immunolabeling in macrophages or preosteoclasts. At 42 postoperative days, matured bone trabeculae were observed (Figure). RANK expression was not present (Figure 2(d)).

#### 3.2. Controls
The negative and positive controls, showed the specificity of the reactions applied. The positive controls were performed in slices from the rat nasal cavities, an area in which RANK expression is observed in macrophages, showing the specificity of the antibody used in the immunolabeling of preosteoclast lineage cells.

In addition, to evaluate the possibility of RANK protein expression in osteoblast-lineage cells, immunohistochemical reactions were performed in the rat embryo at 21 days of pregnancy. A bodily structure that expresses only osteoblast-lineage cells in primary bone tissue is the palatine process. This process was also analyzed as a positive control and showed positive immunolabeling for RANK protein (Figure 3). The immunomarkings shown in Image 3 refer to the RANK immunomarkings in areas outside of the studied area, functioning as positive control to show the effectiveness of the antibody used. Figure 3(a) shows the RANK expression in osteoclasts of the nasal mucosa of rats, and Figure 3(b) shows the RANK expression in osteoblasts in the primary bone tissue of rat embryos. These two regions outside of the studied area are regions that are known to have a large quantity of osteoclasts in the nasal cavity and a large quantity of osteoblasts in rat embryos. Therefore, the specificity of the antibody used is confirmed.

**Quantitative Immunohistochemistry Analysis.** Figure 4 shows the mean values \((M)\) and the standard deviation \((SD)\) for GI and GII during different periods analysed.

Statistically significant difference was observed between GI and GII at 7 and 14 postoperative days \((P = .0109; and .0420, \text{ resp.})\). Significant difference was also observed between GI at 7 and GI at 14 days \((P = .0012)\) (Figure 4).

### 4. Discussion

Several aspects must be considered in the results observed. Immunohistochemistry is a methodological approach that was recently introduced in the study of the bone-repair process [20]. Since then, it has been used consistently, as it allows the proteins present in cells to be identified, thus contributing to a better understanding of bone biology.

The use of frozen sections was chosen, as this type of procedure allows for a greater preservation of tissue antigencity, giving better results of the labels observed. Therefore, it must be considered that positive and negative controls were performed with the aim of evaluating the absence of unspecific labels, as well as specificity of labels in the primary antibody used.

The interface formed between bone and implant has been most studied and discussed by many research centers. Considering that human bone tissue undergoes complete reconstitution of the previous stage of injury, Walter and Talbot [21] used the expression regeneration, instead of repair process. Moreover, the regeneration process at the interface occurs in the following three steps: hemostasis, granulation tissue formation, and bone formation [22, 23].

The primary function of the interface formed between the bone and implant is to provide a safe and efficient charge transfer through the implant to the bone tissue [24]. Many studies have determined the factors that interfere in this interface, among them, the type of surface, showing that the different surface treatments have positive effects on the initial bone repair in animals [25–28] and in humans [29]. Therefore, the purpose of this study was to evaluate the machined surface implants, since the primary aim was to evaluate the cellular responses during the osseointegration process, considering RANK expression and not to compare the topographical modifications of implant surfaces.

The results showed that RANK protein was expressed in different ways during the analyzed periods. The manner that it was expressed was related to the dynamics of the bone remodeling process. Studies have shown that RANK is a receptor protein expressed in macrophages of the osteoclast lineage, dendritic cells, and fibroblasts [14, 30, 31]. In the
Figure 1: Hematoxylin and eosin staining as a reference of the cytoarchitecture of the tissue. ((a) 63x; (b) 160x). Bone tissue formed around the implant at 21 days postoperative.

Figure 2: RANK immunolabeling during bone-implant interface healing process during 7 (a), 14 (b), 21 (c), and 42 (d) days postoperative.

Figure 3: Positive controls from RANK expression. (a) Rats nasal cavity showing RANK expression in preosteoclasts lineage cells. (b) Rat embryo with 21 days of pregnancy. A bodily structure that expresses just osteoblasts lineage cells in primary bone tissue is the palatine process.
With regard to the temporal analysis of the osseointegration process, it was observed that after 14 postoperative days, there was a decrease in the expression of RANK proteins in osteoblasts lineage cells, and at 14 and 21 postoperative days, it was observed the RANK immunolabeling in osteocytes and bone-lining cell. At 42 days postoperative, there was no expression of RANK protein in the bone tissue.

The immunohistochemistry approach could raise doubts with regard to the observed results. Therefore, the control reactions confirmed the observed labelings.

Similar results were observed in our laboratory (paper submitted for publication) when RANK expression in osteoblasts during the alveolar healing process in rats. Coincidentally, the larger RANK protein expression in osteoblasts was at 14 days postoperative, a period marked by greater metabolic activity of the cells during the bone healing process.

The results presented herein showed that osteoblast-lineage cells express RANK protein in primary bone during the initial periods of the bone-healing process around titanium implants.

Acknowledgment

The authors would like to thank FAPESP and CAPES for financial support.

References

[1] K. W. Higuchi, "Ortho-integration: the alliance between orthodontics and osseointegration," in Orthodontic Application of Osseointegrated Implants 2000, K. W. Higuchi, Ed., pp. 1–20, Quintessence, Hong Kong, China, 2000.
[2] P. I. Bränemark, G. A. Zarb, and T. Albrektsson, Tissue Integrated Prostheses: Osseointegration in Clinical Dentistry, Quintessence, Chicago, Ill, USA, 1985.
[3] J. Hollinger and M. E. K. Wong, “The integrated processes of hard tissue regeneration with special emphasis on fracture healing,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 82, no. 6, pp. 594–606, 1996.
[4] C. Ferguson, E. Alpern, T. Miclau, and J. A. Helms, “Does adult fracture repair recapitulate embryonic skeletal formation?” Mechanisms of Development, vol. 87, no. 1-2, pp. 57–66, 1999.
[5] J. E. Davies, Bone Engineering, Squared, Toronto, Canada, 2000.
[6] J. E. Davies, “Understanding peri-implant endosseous healing,” Journal of Dental Education, vol. 67, no. 8, pp. 932–949, 2003.
[7] W. E. Roberts and L. P. Garetto, “Bone PHysiology and metabolism,” in Contemporary Implant Dentistry, C. E. Misch, Ed., pp. 225–237, Mosby, St. Louis, Mo, USA, 1999.
[8] P. S. P. Carvalho, S. B. Jaef, and M. G. Sanches, "Histological study in dogs of small diameter implants system TF, “ JBC—Jornal Brasileiro de Clínica Odontológica Integrada, vol. 1, pp. 21–24, 1997.
[9] R. S. Faeda, H. S. Tavares, R. Sartori, A. C. Guastaldi, and E. Marcantonio Jr., "Biological performance of chemical hydroxyapatite coating associated with implant surface modification by laser beam: biomechanical study in rabbit tibias," Journal of Oral and Maxillofacial Surgery, vol. 67, no. 8, pp. 1706–1715, 2009.
[10] L. Carlsson, T. Röslund, B. Albrektsson, and T. Albrektsson, "Removal torques for polished and rough titanium implants," *The International Journal of Oral & Maxillofacial Implants*, vol. 3, no. 1, pp. 21–24, 1988.

[11] P. R. Klokkevold, R. D. Nishimura, M. Adachi, and A. Caputo, "Osseointegration enhanced by chemical etching of the titanium surface: a torque removal study in the rabbit," *Clinical Oral Implants Research*, vol. 8, no. 6, pp. 442–447, 1997.

[12] L. Meirelles, F. Currie, M. Jacobsson, T. Albrektsson, and A. Wennenerberg, “The effect of chemical and nanotopographical modifications on the early stages of osseointegration,” *International Journal of Oral and Maxillofacial Implants*, vol. 23, no. 4, pp. 641–647, 2008.

[13] Y. L. Ma, R. L. Cain, D. L. Halladay et al., “Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation,” *Endocrinology*, vol. 142, no. 9, pp. 4047–4054, 2001.

[14] S. Khosla, “Minireview: the OPG/RANKL/RANK system,” *Endocrinology*, vol. 142, no. 12, pp. 5050–5055, 2001.

[15] D. Stejskal, J. Bartek, R. Pastorkova, V. Ruzicka, I. Oral, and D. Horalik, “Osteoprotegerin, RANK, RANKL,” *Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia*, vol. 145, no. 2, pp. 61–64, 2001.

[16] T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, and T. J. Martin, “Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families,” *Endocrine Reviews*, vol. 20, no. 3, pp. 345–357, 1999.

[17] T. Kaneda, T. Nojima, M. Nakagawa et al., “Endogenous production of TGF-β is essential for osteoclastogenesis induced by a combination of receptor activator of NF-κB ligand and macrophage-colony-stimulating factor,” *Journal of Immunology*, vol. 165, no. 8, pp. 4254–4263, 2000.

[18] N. Takahashi, N. Udagawa, and T. Suda, “A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function,” *Biochemical and Biophysical Research Communications*, vol. 256, no. 3, pp. 449–455, 1999.

[19] National Research Council, “Guide for the care and use of laboratory animals,” DHHS Publication (NIH) 85–23, Department of Health and Human Services, NRC, Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, 1985.

[20] H. Devlin, J. Hoyland, J. F. Newall, and S. Ayad, “Trabecular bone formation in the healing of the rodent molar tooth extraction socket,” *Journal of Bone and Mineral Research*, vol. 12, no. 12, pp. 2061–2067, 1997.

[21] J. B. Walter and J. C. Talbot, “Wound healing,” in *Walter & Israel General Pathology* 1996, pp. 65–180, Churchill Livingstone, New York, NY, USA, 7th edition, 1996.

[22] J. E. Davies, “Mechanisms of endosseous integration,” *International Journal of Prosthodontics*, vol. 11, no. 5, pp. 391–401, 1998.

[23] P. S. P Carvalho and D. Ponzoni, “Biological aspects of osseointegration,” in *Dental Implants: Technique and Art* 2002, L. A. Gomes, Ed., pp. 1–9, Santos, São Paulo, Brazil, 2002.

[24] J. B. Brunski, “Biomechanics of oral implants: future research directions,” *Journal of Dental Education*, vol. 52, no. 12, pp. 775–787, 1988.

[25] G. Watzek, W. Zechner, C. Ulm, S. Tangl, G. Tepper, and G. Watzek, “Histologic and histomorphometric analysis of three types of dental implants following 18 months of occlusal loading: a preliminary study in baboons,” *Clinical Oral Implants Research*, vol. 16, no. 4, pp. 408–416, 2005.

[26] W. Zechner, M. Kneissl, S. Kim, C. Ulm, G. Watzek, and H. Plenk Jr., “Histomorphometrical and clinical comparison of submerged and nonsubmerged implants subjected to experimental peri-implantitis in dogs,” *Clinical Oral Implants Research*, vol. 15, no. 1, pp. 23–33, 2004.

[27] W. Zechner, S. Tangl, G. Fürst et al., “Osseous healing characteristics of three different implant types,” *Clinical Oral Implants Research*, vol. 14, no. 2, pp. 150–157, 2003.

[28] A. B. Novaes Jr., S. L. S. Souza, P. T. de Oliveira, and A. M. M. Souza, “Histomorphometric analysis of the bone-implant contact obtained with 4 different implant surface treatments placed side by side in the dog mandible,” *International Journal of Oral and Maxillofacial Implants*, vol. 17, no. 3, pp. 377–383, 2002.

[29] D. L. Cochran, “A comparison of endosseous dental implant surfaces,” *Journal of Periodontology*, vol. 70, no. 12, pp. 1523–1539, 1999.

[30] H. Hsu, D. L. Lacey, C. R. Dunstan et al., “‘Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,’” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 7, pp. 3540–3545, 1999.

[31] J. Li, I. Sarosi, X.-Q. Yan et al., “RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 4, pp. 1566–1571, 2000.

[32] A. R. Pettit, N. C. Walsh, C. Manning, S. R. Goldring, and E. M. Gravallese, “RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis,” *Rheumatology*, vol. 45, no. 9, pp. 1068–1076, 2006.